New drug shows promise for kidney disease in early trial

NCT ID NCT05834738

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 31, 2026 · Last updated Apr 30, 2026 · Updated 10 times

Summary

This study tested an experimental drug called atrasentan in 54 adults with IgA nephropathy, a kidney disease. All participants were already on standard treatments, including SGLT2 inhibitors. The goal was to see if adding atrasentan could further reduce protein in the urine, a sign of kidney damage. The trial was a phase 2 crossover study, meaning each person received both atrasentan and a placebo at different times to compare effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Chung-Ang University College

Seoul, Seoul, 06973, South Korea
Dong-A University Medical Center (Dong-A University Hospital)

Busan, Busan, 49201, South Korea
Fides Clinical Research

Atlanta, Georgia, 30342, United States
Hallym University Sacred Heart Hospital

Anyang-si, Gyeonggi-do, 14068, South Korea
Hopsital Sultanah Aminah Johor Bharu (HSAJB) - Bangunan Bakawali Heodialysis Centre

Johor Bahru, Johor Darul Takzim, 80100, Malaysia
Hospital 12 de Octubre

Madrid, 28041, Spain
Hospital Clinico Universitario

Valencia, 46010, Spain
Hospital Raja Permaisuri Bainun (HRPB)

Ipoh, Perak, 30450, Malaysia
Hospital Ribera Polusa

Lugo, 27004, Spain
Hospital Torrecardenas

Almería, 04009, Spain
Hospital Universitario De Getafe (HUG)

Madrid, 28009, Spain
Hospital Virgen Macarena

Seville, 41009, Spain
Hospital das Clinicas da Faculdade de Medicina da USP

São Paulo, São Paulo, 05403-000, Brazil
Hospital del Mar

Barcelona, 08003, Spain
Hospital del Vall d´Hebron

Barcelona, 08035, Spain
Monash Health- Monash Medical Centre

Melbourne, Victoria, 3168, Australia
NANI Research

Oak Brook, Illinois, 60523, United States
NUPEC Cardio

Belo Horizonte, Minas Gerais, 30220-140, Brazil
Prince of Wales Hospital

Sydney, New South Wales, 2031, Australia
Santa Casa de Misericordia de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90035-074, Brazil
Soon Chun Hyang Central Medical Center (SCHMC) - Soon Chun Hyang University Hospital

Cheonan, Chungnam-Do, 31151, South Korea
Sunshine Hospital

St Albans, Victoria, 3021, Australia
The St. George Hospital

Kogarah, New South Wales, 2217, Australia
Tufts Medical Center

Boston, Massachusetts, 02111, United States
Universidade Federal de Sao Paulo

São Paulo, São Paulo, 04038-002, Brazil
Universiti Kebangsaan Malaysia (UKM) - Medical Centre (Pusat Perubatan) (Hospital Canselor Tuanku Muhriz (HCTM))

Cheras, Kuala Lumpur, 56000, Malaysia
University Malaya Medical Centre

Kuala Lumpur, Kuala Lumpur, 59100, Malaysia
University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC) - Nephrology Clinic

Birmingham, Alabama, 35233, United States
University of North Carolina at Chapel Hill - Nephrology and Hypertension

Chapel Hill, North Carolina, 27599, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.

IGA NEPHROPATHY IGA NEPHROPATHY IMMUNOGLOBULIN A NEPHROPATHY